Shockwave Medical, Inc. (NASDAQ:SWAV) Stock Holdings Reduced by Geneva Capital Management LLC

Geneva Capital Management LLC reduced its stake in shares of Shockwave Medical, Inc. (NASDAQ:SWAV - Free Report) by 13.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,052 shares of the company's stock after selling 5,578 shares during the quarter. Geneva Capital Management LLC owned approximately 0.10% of Shockwave Medical worth $6,870,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Lindbrook Capital LLC boosted its stake in Shockwave Medical by 64.8% in the 3rd quarter. Lindbrook Capital LLC now owns 150 shares of the company's stock worth $30,000 after purchasing an additional 59 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Shockwave Medical by 297.4% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company's stock worth $31,000 after purchasing an additional 116 shares in the last quarter. Asset Management One Co. Ltd. bought a new position in Shockwave Medical in the 4th quarter worth about $34,000. Operose Advisors LLC bought a new position in Shockwave Medical in the 3rd quarter worth about $49,000. Finally, Venturi Wealth Management LLC bought a new position in Shockwave Medical during the 3rd quarter valued at about $82,000. 95.35% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Shockwave Medical

In related news, Director Laura Francis sold 1,500 shares of the company's stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $300.00, for a total value of $450,000.00. Following the completion of the sale, the director now directly owns 3,551 shares of the company's stock, valued at $1,065,300. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Shockwave Medical news, Director Laura Francis sold 1,500 shares of the stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $300.00, for a total transaction of $450,000.00. Following the completion of the sale, the director now directly owns 3,551 shares of the company's stock, valued at $1,065,300. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Trinh Phung sold 599 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $259.24, for a total transaction of $155,284.76. Following the sale, the vice president now directly owns 31,031 shares of the company's stock, valued at $8,044,476.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 83,120 shares of company stock valued at $21,319,021. 3.40% of the stock is currently owned by corporate insiders.

Shockwave Medical Trading Up 0.0 %

Shockwave Medical stock traded up $0.01 during mid-day trading on Friday, hitting $330.55. The company's stock had a trading volume of 429,386 shares, compared to its average volume of 1,183,588. Shockwave Medical, Inc. has a one year low of $157.00 and a one year high of $331.58. The stock has a market cap of $12.40 billion, a PE ratio of 77.23, a P/E/G ratio of 2.45 and a beta of 0.88. The company has a 50 day moving average of $308.48 and a 200-day moving average of $242.19. The company has a debt-to-equity ratio of 1.09, a quick ratio of 10.73 and a current ratio of 11.76.

Shockwave Medical (NASDAQ:SWAV - Get Free Report) last released its quarterly earnings data on Monday, May 6th. The company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.45. Shockwave Medical had a net margin of 20.75% and a return on equity of 26.00%. The company had revenue of $218.80 million during the quarter, compared to analysts' expectations of $207.69 million. During the same period in the previous year, the company earned $1.03 EPS. The firm's quarterly revenue was up 35.8% on a year-over-year basis. On average, research analysts anticipate that Shockwave Medical, Inc. will post 4.94 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Wolfe Research reaffirmed a "peer perform" rating on shares of Shockwave Medical in a research report on Friday, April 5th. Morgan Stanley reaffirmed an "equal weight" rating and set a $335.00 price target (up previously from $285.00) on shares of Shockwave Medical in a research report on Monday, April 8th. SVB Leerink reaffirmed a "market perform" rating and set a $335.00 price target (down previously from $361.00) on shares of Shockwave Medical in a report on Monday, April 8th. CL King reissued a "neutral" rating on shares of Shockwave Medical in a research note on Monday, April 8th. Finally, TheStreet raised shares of Shockwave Medical from a "c+" rating to a "b" rating in a report on Thursday, February 15th. Ten equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $309.11.

About Shockwave Medical

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.